<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ptc Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/ptc-therapeutics-inc</link>
<description>Latest news and press releases for Ptc Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ptc-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b20578dffbe2df1115d5.webp</url>
<title>Ptc Therapeutics Inc</title>
<link>https://6ix.com/company/ptc-therapeutics-inc</link>
</image>
<item>
<title>PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam</guid>
<pubDate>Tue, 28 Apr 2026 20:05:00 GMT</pubDate>
<description>PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for Stage 2 Huntington's disease (HD) patients following 24 months of votoplam treatment compared to an external natural history cohort.</description>
</item>
<item>
<title>PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to</description>
</item>
<item>
<title>PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-appoints-biotech-banking-pioneer-jessica-chutter-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-appoints-biotech-banking-pioneer-jessica-chutter-to-board-of-directors</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of</description>
</item>
<item>
<title>PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-corporate-update-and-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
<description>PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.</description>
</item>
<item>
<title>PTC Therapeutics Provides Regulatory Update on Translarna™</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-regulatory-translarna-220000155</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-regulatory-translarna-220000155</guid>
<pubDate>Thu, 12 Feb 2026 22:00:00 GMT</pubDate>
<description>PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) following U.S. Food and Drug Administration (FDA) feedback on the application review.</description>
</item>
<item>
<title>PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-report-fourth-quarter-130000854</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-report-fourth-quarter-130000854</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET.</description>
</item>
<item>
<title>PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-j-p-133000897</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-j-p-133000897</guid>
<pubDate>Mon, 12 Jan 2026 13:30:00 GMT</pubDate>
<description>PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the Company's presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026, at 9:00 a.m. PST / 12:00 p.m. EST.</description>
</item>
<item>
<title>PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-reports-inducement-grants-213000122</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-reports-inducement-grants-213000122</guid>
<pubDate>Thu, 08 Jan 2026 21:30:00 GMT</pubDate>
<description>PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee. The award was made pursuant to the Nasdaq inducement grant exception as a component of the new hire's employment compensation.</description>
</item>
<item>
<title>PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-announces-approval-sephiencetm-sepiapterin-treatment-children-and</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-announces-approval-sephiencetm-sepiapterin-treatment-children-and</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>– Indication includes all ages and the full spectrum of disease severity –– First Japan product approval for PTC – WARREN, N.J., Dec. 22, 2025 /PRNewswire/ --</description>
</item>
<item>
<title>PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>WARREN, N.J., Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44th</description>
</item>
<item>
<title>PTC Therapeutics Announces Health Canada Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-announces-health-canada-130000437</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-announces-health-canada-130000437</guid>
<pubDate>Wed, 10 Dec 2025 13:00:00 GMT</pubDate>
<description>PTC Therapeutics Canada ULC announced that Health Canada has approved Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The approval includes broad labeling for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month old and older with sepiapterin-responsive PKU.</description>
</item>
<item>
<title>Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/cadrenal-therapeutics-appoints-dr-lee-golden-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/cadrenal-therapeutics-appoints-dr-lee-golden-to-board-of-directors</guid>
<pubDate>Mon, 01 Dec 2025 14:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),</description>
</item>
<item>
<title>PTC Therapeutics to Host R&D Day</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-host-rd-day-2025-11-20</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-host-rd-day-2025-11-20</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>Event to take place on Dec. 2, 2025 in New York City WARREN, N.J., Nov. 20, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that</description>
</item>
<item>
<title>PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>– Initiated US and EU launch of Sephience™ (sepiapterin) – – Strong initial Sephience uptake with global revenue of $19.6M and 521 start forms in the US as</description>
</item>
<item>
<title>PTC Therapeutics to Participate at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-participate-upcoming-investor-conferences-2025-10-31</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-participate-upcoming-investor-conferences-2025-10-31</guid>
<pubDate>Fri, 31 Oct 2025 04:00:00 GMT</pubDate>
<description>WARREN, N.J., Oct. 31, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following</description>
</item>
<item>
<title>PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-host-conference-call-discuss-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-host-conference-call-discuss-third-quarter-2025-financial-results</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>WARREN, N.J., Oct. 21, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to</description>
</item>
<item>
<title>Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/pyxis-oncology-appoints-alex-kane-as-senior-vice-president-investor-relations-and-capital-markets</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/pyxis-oncology-appoints-alex-kane-as-senior-vice-president-investor-relations-and-capital-markets</guid>
<pubDate>Thu, 09 Oct 2025 11:30:00 GMT</pubDate>
<description>BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capital Markets, effective immediately. Mr. Kane brings 20 years of experience and a proven track record in investor relations, strategic communications, and equity capital markets across the life sciences sector</description>
</item>
<item>
<title>RareMed Announces Expansion of Relationship with PTC Therapeutics</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/raremed-announces-expansion-of-relationship-with-ptc-therapeutics-1</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/raremed-announces-expansion-of-relationship-with-ptc-therapeutics-1</guid>
<pubDate>Tue, 02 Sep 2025 14:53:00 GMT</pubDate>
<description>RareMed Solutions®, the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics™ with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience™. The recent approval of Sephience by the FDA marks a significant milestone in the treatment of phenylketonuria (PKU) for both adult and pediatric patients. This new therapy, developed by PTC, has the potential to transform the lives of tho</description>
</item>
<item>
<title>PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-receives-complete-response-letter-vatiquinone-nda-2025-08-19</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-receives-complete-response-letter-vatiquinone-nda-2025-08-19</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>WARREN, N.J., Aug. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the U.S. Food and Drug Administration (FDA) has issued</description>
</item>
<item>
<title>PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial</link>
<guid isPermaLink="true">https://6ix.com/company/ptc-therapeutics-inc/news/ptc-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>– European and FDA approval of Sephience™ (sepiapterin) with broad labeling for PKU – – Global launch underway in Europe and U.S. – – Total Q2 Revenue of</description>
</item>
</channel>
</rss>